NASDAQ · ACCD
Accolade, Inc.
$7.02$0.00 (0.0%)
Accolade, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.4% below the high.
Loading market information…
NASDAQ · SLGC · USD
Stock price, earnings
Quote as of Jan 5, 2024, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
SomaLogic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.59% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow SomaLogic, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SomaLogic, Inc. is a U.S.-based enterprise specializing in the identification of protein biomarkers and the development of clinical diagnostic solutions. A core aspect of its technology involves the creation of slow off-rate modified aptamers (SOMAmers) – unique nucleic acid-based reagents meticulously designed to specifically bind with their target proteins. The company also provides its proprietary SomaScan services, which enable the simultaneous detection and precise quantification of numerous proteins within intricate biological samples. This integrated SOMAmer and SomaScan platform empowers researchers to analyze diverse biological specimens, uncovering protein biomarker signatures invaluable for pharmaceutical discovery and development initiatives. Furthermore, the biomarker insights gleaned from SomaScan are instrumental in developing diagnostic applications across a range of conditions, such as cardiovascular and metabolic diseases, nonalcoholic steatohepatitis (NASH), and for general wellness monitoring. SomaLogic additionally furnishes SomaSignal tests, available for both research use only (RUO) and as laboratory-developed tests (LDTs). The firm caters to both research and clinical clients, primarily comprising pharmaceutical and biotechnology companies, as well as academic research institutions. These offerings support various stages of drug development, facilitate the analysis of clinical trials, and contribute to novel insights into human biology through the investigation of protein-protein and protein-gene interactions. Established in 1999, SomaLogic maintains its corporate headquarters in Boulder, Colorado.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:32 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2022 | May 12, 2022 | -$0.150.0% vs estimate | $22.98M |
|---|
| Q4 2021 | Mar 29, 2022 | -$0.16-33.33% vs estimate | $22.99M+16.31% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.02$0.00 (0.0%)
Accolade, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.4% below the high.
$1.43-$0.01 (-0.35%)
Sharecare, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
$23.53-$0.47 (-1.96%)
Claritev Corporation’s quoted price sits in the lower half of its reported 52-week range, 68.06% below the high.
$3.65$0.00 (0.0%)
Revance Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.72% below the high.
$16.70+$0.05 (+0.3%)
Orchard Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$7.16+$0.01 (+0.14%)
G1 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.42% below the high.
$8.05$0.00 (0.0%)
Vigil Neuroscience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
$4.26$0.00 (0.0%)
Checkpoint Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.33% below the high.
